Andelyn to Support Manufacturing Scaleup for Genprex’s Diabetes Gene Therapy
Under the agreement, Andelyn will transition Genprex's adeno-associated virus (AAV)-based diabetes gene therapy candidate with process optimization, scale-up, and IND-enabling and clinical-stage manufacturing to support clinical trials. The post Andelyn to Support Manufacturing Scaleup for Genprex’s Diabetes Gene Therapy appeared first on GEN - Genetic Engineering and Biotechnology News .
Genprex has chosen Andelyn Biosciences to help scale up manufacturing for its diabetes gene therapy program. The therapy, which aims to deliver the Pdx1 and MafA genes to the pancreas via an AAV vector, could treat both type 1 and type 2 diabetes. Andelyn will optimize processes, scale up production, and prepare the therapy for clinical trials, leveraging its expertise in AAV development and cGMP manufacturing.
In type 1 diabetes, the therapy aims to turn alpha cells into beta-like cells that produce insulin. Preclinical studies in mice have shown restored blood glucose levels and reduced insulin needs. For type 2 diabetes, the therapy could rejuvenate exhausted insulin-producing beta cells. Andelyn's CEO, Matt Niloff, expressed enthusiasm for supporting Genprex's program, while Genprex's CEO, Ryan Confer, highlighted the importance of Andelyn's AAV development experience for IND-enabling studies and clinical evaluation.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
